Cangrelor in patients undergoing cardiac surgery: the BRIDGE study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Long-term dual antiplatelet therapy (DAPT) is crucial for patients with acute coronary syndromes, drug-eluting stents, and high thromboembolic risk.
• Novel antiplatelet agents are under development to improve clinical outcomes.
• A therapeutic gap exists when patients on DAPT require surgery, necessitating temporary discontinuation of their medication.

Purpose of the Study:

• To evaluate the efficacy and safety of cangrelor as a bridge therapy for patients undergoing coronary artery bypass graft (CABG) surgery while on extended DAPT.

Main Methods:

• The study involved patients receiving extended DAPT who required temporary cessation of therapy for CABG surgery.
• Cangrelor was administered as a bridge therapy during the interruption of oral antiplatelet agents.

Main Results:

• The BRIDGE trial confirmed the efficacy of cangrelor in preventing thrombotic events in this high-risk population.
• Cangrelor demonstrated a favorable safety profile, with no significant increase in bleeding complications.

Conclusions:

• Cangrelor serves as an effective and safe option to bridge patients on DAPT during CABG surgery.
• The findings support the use of cangrelor to manage antiplatelet therapy interruptions in specific surgical contexts.
• Future research should explore cangrelor's role in bridging for non-CABG surgical procedures in high-risk patients.